Altimmune, Inc.

Related records

Trials (19)

• ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
• ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
• ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
• Efficacy and Safety of ALT-801 in the Treatment of Obesity
• Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
• HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
• Immune Response Following Seasonal Influenza Vaccination
• IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
• NasoShield in Healthy Adults to Study Safety and Immunogenicity
• NasoShield Study of Safety and Immunogenicity
• NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
• Pemvidutide (ALT-801) DDI Study in Healthy Volunteers
• Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B
• RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
• RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
• Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)
• Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
• Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
• Study of the Safety and Immunogenicity of NasoVAX Extension